Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1

Conditions

Opioid-Related Disorders 1Neoplasms 1Constipation 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Has results × methylnaltrexone × Clear all
NCT01004393 2016-02-02

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

University of Vermont

Phase 2 Completed
12 enrolled 10 charts
Other

Constipation, Opioid-Related Disorders, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡